John E. Imhoff, a director and ten percent owner of Guided Therapeutics Inc. (OTC:GTHP), has made a significant purchase of the company’s stock. According to a recent SEC filing, Imhoff acquired 1,615,385 shares of common stock along with warrants to purchase an additional 1,615,385 shares. The transaction, completed on December 18, 2024, was executed at an aggregate purchase price of $210,000. The micro-cap company, currently valued at approximately $7.8 million, has seen its stock price rise nearly 29% over the past year despite showing high price volatility.
The warrants, which were immediately exercisable upon issuance, have an exercise price of $0.18 per share and will expire four years from the issuance date. Following this transaction, Imhoff’s direct ownership in Guided Therapeutics increased, reflecting his continued confidence in the company’s prospects.
Investors may view this acquisition as a positive signal, considering Imhoff’s dual role as both a director and a significant shareholder. Guided Therapeutics, headquartered in Peachtree Corners, Georgia, is known for its work in the electromedical and electrotherapeutic apparatus industry.
In other recent news, Guided Therapeutics, Inc. has reported significant progress with its LuViva Advanced Cervical Scan device. The company’s Chinese partner, Shandong Yaohua Medical (TASE:PMCN) Instrument Corporation, has submitted an application for the device to the Chinese National Medical Products Administration (NMPA). The application is backed by a study involving 449 women at four top medical institutions in China, which demonstrated LuViva’s diagnostic performance, with a sensitivity of 83% for detecting cervical precancers and cancers, and a specificity of 54%.
These results suggest that LuViva could enhance cervical disease diagnosis and screening, potentially reducing unnecessary biopsies. The CEO of Guided Therapeutics, Mark Faupel, has expressed optimism about the study’s outcome and its implications for the ongoing US FDA study, which uses the same technology and artificial intelligence algorithms. The company is also looking forward to a positive decision from the Chinese NMPA, which could significantly boost its market presence in China.
The NMPA filing also strengthens the partnership between Guided Therapeutics and Shandong Yaohua Medical Instrument Corporation, paving the way for an estimated $125 million in revenue from devices, disposables, services, and royalties over the next six years. These are the latest developments in the company’s ongoing efforts to provide early disease detection at the cellular level.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.